These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7850539)

  • 21. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.
    Pace M; Gattai R; Mascitelli EM; Millanta L
    J Surg Oncol; 2011 Dec; 104(7):718-23. PubMed ID: 21721008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylactic hyperthermic limb perfusion in stage I melanoma.
    Krige JE; King HS; Strover RM
    Eur J Surg Oncol; 1988 Aug; 14(4):321-6. PubMed ID: 3044834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of the extremities.
    Schraffordt Koops H; Kroon BB; Oldhoff J; Hoekstra HJ
    World J Surg; 1992; 16(2):241-5. PubMed ID: 1561805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperthermic perfusion of recurrent malignant melanoma on the extremities.
    Hafström L; Jönsson PE
    Acta Chir Scand; 1980; 146(5):313-8. PubMed ID: 7468061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
    Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
    Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion.
    Cheng TY; Grubbs E; Abdul-Wahab O; Leu SY; Hung CF; Petros W; Aloia T; Fedrau R; Pruitt S; Colvin M; Friedman H; Tyler D
    Am J Surg; 2003 Nov; 186(5):460-7. PubMed ID: 14599607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.
    Lasithiotakis K; Economou G; Gogas H; Ioannou C; Perisynakis K; Filis D; Kastana O; Bafaloukos D; Decatris M; Catodritis N; Frangia K; Papadakis G; Magarakis M; Tsoutsos D; Chrysos E; Chalkiadakis G; Zoras O
    Oncol Rep; 2010 Apr; 23(4):1077-83. PubMed ID: 20204294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities--long-term follow-up of a randomised trial.
    Olofsson Bagge R; Mattsson J; Hafström L
    Int J Hyperthermia; 2014 Aug; 30(5):295-8. PubMed ID: 25144818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs.
    Vrouenraets BC; Eggermont AM; Klaase JM; Van Geel BN; Van Dongen JA; Kroon BB
    Eur J Surg Oncol; 1994 Dec; 20(6):681-5. PubMed ID: 7995421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperthermic perfusion in malignant melanoma: 5-year results.
    Tonak J; Hohenberger W; Weidner F; Göhl H
    Recent Results Cancer Res; 1983; 86():229-38. PubMed ID: 6648004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients.
    Knorr C; Meyer T; Janssen T; Goehl J; Hohenberger W
    Eur J Surg Oncol; 2006 Mar; 32(2):224-7. PubMed ID: 16289716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma.
    Kroon HM; Lin DY; Kam PC; Thompson JF
    Ann Surg; 2009 Jun; 249(6):1008-13. PubMed ID: 19474677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities.
    Boesch CE; Meyer T; Waschke L; Merkel S; Goehl J; Hohenberger W; Knorr C
    Int J Hyperthermia; 2010 Feb; 26(1):16-20. PubMed ID: 20100048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb.
    Rauschecker HF; Foth H; Michaelis HC; Horst F; Gatzemeier W; Willenbrock C; Voth E; Kahl GF
    Cancer Chemother Pharmacol; 1991; 27(5):379-84. PubMed ID: 1998997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional morbidity after regional isolated perfusion of the limb for melanoma.
    van Geel AN; van Wijk J; Wieberdink J
    Cancer; 1989 Mar; 63(6):1092-6. PubMed ID: 2917313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Surgical treatment and regional chemotherapy in melanoma of the extremities].
    Henneking K; Binder J; Weyers W; Schwemmle K
    Chirurg; 1993 Feb; 64(2):134-8. PubMed ID: 8462350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan.
    Zwaveling JH; Maring JK; Clarke FL; van Ginkel RJ; Limburg PC; Hoekstra HJ; Koops HS; Girbes AR
    Crit Care Med; 1996 May; 24(5):765-70. PubMed ID: 8706451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of hyperthermic perfusion for melanoma of the extremities.
    Stehlin JS; Giovanella BC; de Ipolyi PD; Muenz LR; Anderson RF
    Surg Gynecol Obstet; 1975 Mar; 140(3):339-48. PubMed ID: 1114425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
    Lejeune FJ; Eggermont AM
    J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.